Mercy BioAnalytics
Waltham, Massachusetts, United States · Biotechnology · 47 employees
Mercy BioAnalytics, Inc. is on a mission to relieve suffering and save lives through the early detection of cancer. Early-stage cancer is difficult to detect, but when found, is more often amenable to curative therapy. The patented Mercy Halo™ liquid biopsy platform utilizes biomarker co-localization to interrogate highly abundant, blood-based extracellular vesicles that carry unique cancer signat
Funding history
- Series series b — $59.0M — Sep 2025
- Funding Round — $27.3M — Feb 2021
Recent signals
- Dec 04, 2025: Mercy BioAnalytics Appoints Ellen Snow as Chief Financial Officer
- Sep 03, 2025: Raised $59.0M in Series series b
- Jul 08, 2025: Mercy BioAnalytics Appoints Prasanth Reddy as Chief Medical Officer
- Feb 01, 2021: Raised $27.3M
See plans & pricing → Track Mercy BioAnalytics’s funding, hiring, and signals — with verified contacts — on Fundz.